Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amitriptyline + clozapine is a combination of two small molecule drugs, amitriptyline and clozapine. Amitriptyline is a tricyclic antidepressant with anticholinergic and sedative properties, primarily used for depression, neuropathic pain, and off-label for conditions such as fibromyalgia. Its mechanism involves inhibition of serotonin and norepinephrine reuptake transporters in the central nervous system. Clozapine is an atypical antipsychotic indicated for treatment-resistant schizophrenia; it acts mainly by antagonizing dopamine D2 receptors and serotonin 5-HT2A receptors, among others. The combination may be considered in rare clinical scenarios (e.g., using low-dose amitriptyline to manage clozapine-induced sialorrhea), but carries significant risk due to major drug-drug interactions that can lead to toxic serum levels or severe adverse effects such as pulmonary toxicity[1][2][4]. Both drugs are metabolized by cytochrome P450 enzymes (notably CYP2D6), increasing the risk of pharmacokinetic interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amitriptyline + clozapine.